TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01092065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056 with L-dopa
Description: hard gelatin capsule to be taken bid for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsule to be taken bid for six weeks
Study: NCT03410264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR-EXP
Description: See arm/group descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXP-CR
Description: See arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: See arm/group descriptions
Study: NCT00540371

Intervention type: OTHER
Intervention: Port wine stain Birthmark
Description: Port wine stain Birthmark
Study: NCT03538574

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: CBT-I is a behavioral treatment for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP-I
Description: MAP-I is a mindfulness meditation treatment for insomnia
Study: NCT03383705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VBeam Prima
Description: Up to four treatments will be performed every 4-6 (±1) weeks.
Study: NCT03761771

Intervention type: DEVICE
Intervention: colonoscopy withdrawal with the ADS monitoring
Description: During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
Study: NCT00064298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit and vegetable extracts
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04211233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: invasive subdural grid electrode
Description: A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Standard Treatment based on Brain Trauma Foundation
Study: NCT04144465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NORADRENALIN
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PHENYLEPHRINE
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Study: NCT04381338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary and Motor Rehabilitation
Description: Pulmonary and Motor Rehabilitation in ICU
Study: NCT01486810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medication management
Description: All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
Study: NCT00983697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study: NCT04651101

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: extent of coronary artery disease in invasive coronary angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: extent of coronary artery disease in invasive coronary angiography
Study: NCT04010539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
Study: NCT01951859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropathy/Ulcer Homeopathic topical cream
Description: This is a GRAS topical agent containing homeopathic ingredients
Study: NCT01216605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01989260

Intervention type: DEVICE
Group type: OTHER
Intervention: Anti-adhesive gel
Description: 4mls of anti-adhesive gel coated to the randomized ovary
Study: NCT04268849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol (30 mg/mL) intravenous injection in single use vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol
Description: Ferumoxytol (30 mg/mL) intravenous injection in single use vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo for Ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo for Ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate tablets containing 60 mg elemental iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate tablets containing 60 mg elemental iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
Study: NCT02045303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Ultrasound Therapy
Description: Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noncontact Ultrasound Therapy
Description: Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
Study: NCT00721903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Scan
Description: 10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography and Ultrasound
Description: To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
Study: NCT02264873

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
Study: NCT04612023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Description: Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
Study: NCT01150474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belladonna and Opium Suppositories
Description: Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Suppositories
Description: Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Study: NCT03533686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhear Bone Conduction System
Description: Non-invasive bone conduction hearing device using adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone anchored hearing aid (BAHA)
Description: Non-invasive bone conduction hearing device using a headband

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone anchored hearing aid (BAHA)
Description: Non-invasive bone conduction hearing device using a headband
Study: NCT01856023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Study: NCT01585012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical cap (Focus Touch™ Conception System)
Description: Cervical cap
Study: NCT01797172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cervical Nucleoplasty
Description: Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radio Frequency
Description: Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
Study: NCT02345746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: infusion over 12 hours via HAI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: as a 2-hour infusion via HAI on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
Study: NCT00384111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin Therapeutic Regimen
Description: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CVP
Description: Standard R-CVP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CVP
Description: Standard R-CVP
Study: NCT00245583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: minimum does of 50mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablet
Study: NCT00868179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradax
Description: Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
Study: NCT00829283

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: weekly individual sessions for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss
Description: weekly individual sessions for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy
Description: weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
Study: NCT01423864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solumedrol
Description: Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
Study: NCT01358448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: growth monitoring
Description: Caretakers will be encouraged to monitor child growth monthly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Monitoring plus Family-based Behavioral Counseling
Description: Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
Study: NCT02246829

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravitreal injection
Description: 2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
Study: NCT01896115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS settings
Description: Deep brain stimulation set at short pulse width and monopolar stimulation using current steering

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS settings
Description: Deep brain stimulation set at short pulse width and monopolar stimulation using current steering

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS settings
Description: Deep brain stimulation set at short pulse width and monopolar stimulation using current steering

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS settings
Description: Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
Study: NCT02954575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Study: NCT06027775

Intervention type: DRUG
Intervention: Targeted agent
Description: The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
Study: NCT02809274

Intervention type: OTHER
Intervention: questionnaires
Description: • Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form

Intervention type: OTHER
Intervention: questionnaires
Description: • Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
Study: NCT01498913

Intervention type: DRUG
Intervention: repaglinide
Description: Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
Study: NCT00275496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Dissection
Description: Subject has wide excision and sentinel lymph node dissection for primary melanoma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Lymph Node Dissection
Description: Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Excision
Description: Subject has wide excision only for primary melanoma.
Study: NCT02343575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS
Study: NCT04249193

Intervention type: OTHER
Intervention: Transfusion
Description: pRBC and non-pRBC transfusions
Study: NCT04576221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stacked breathing exercise
Description: • Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV by CPAP mask
Description: provides pressurized air through a mask to help push air into your lungs and help you breathe
Study: NCT02186171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection once a month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month.
Study: NCT01703221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 50 mg tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg capsule administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin 50 mg tablet administered orally once daily
Study: NCT02343575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg matched to VPA BID PO/NGT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Haloperidol
Description: Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN